Post-induction Therapy for Low-grade or Follicular NHL
After response to first-line treatment of follicular or low-grade NHL
2 years of RITUXAN post-induction therapy is a proactive approach that reduced the risk of progression, relapse, or death by nearly 50%
- *R-CHEMO: Approximately 75% of trial patients in both trial arms received R-CHOP, 22% received R-CVP, and 3% received R-FCM.1
- NHL=non-Hodgkin's lymphoma; PFS=progression-free survival; HR=hazard ratio; R=RITUXAN; PRIMA=Primary RItuximab and MAintenance; CVP=cyclophosphamide, vincristine, and prednisone; ECOG=Eastern Cooperative Oncology Group; CHOP=cyclophosphamide, doxorubicin, vincristine, and prednisone; FCM=fludarabine, cyclophosphamide, and mitoxantrone.
RITUXAN after first-line R-CHEMO in the PRIMA trial1,2
- Patients with advanced follicular NHL were randomized to receive either RITUXAN or no further therapy if they achieved a CR, CRu, or PR with R-CHEMO induction therapy
- At 2-year median follow-up, there was a 46% reduction in the risk of progression, relapse, or death with RITUXAN vs observation (p<0.0001)
- CR=complete response; CRu=complete response, unconfirmed; PR=partial response.
RITUXAN after first-line CVP in the ECOG 1496 trial1,2
- Patients with advanced low-grade NHL were randomized to receive either RITUXAN or no further therapy if they achieved a CR, PR, or SD with CVP induction therapy
- At 2.3-year median follow-up, there was a 51% reduction in the risk of progression, relapse, or death with RITUXAN vs observation
- SD=stable disease.
Single-agent RITUXAN as maintenance for follicular NHL after first-line RITUXAN-based chemotherapy
- Detailed safety data collection was limited to Grade ≥2 infections, Grade ≥3 adverse reactions, and serious adverse reactions
- The most common Grade 3-4 adverse reactions occurring at a higher incidence (≥2%) in the RITUXAN arm than in the observation arm were infections (4% vs. 1%) and neutropenia (4% vs. <1%)
- The most frequently reported adverse reaction was infections. In patients receiving RITUXAN as single-agent maintenance therapy following RITUXAN plus chemotherapy, infections were reported more frequently compared with the observation arm (37% vs. 22%)
Single-agent RITUXAN for low-grade NHL after first-line CVP chemotherapy
- Neutropenia was the only Grade 3 or 4 adverse reaction that occurred more frequently (≥2%) in the RITUXAN arm compared with those who received no further therapy (4% vs. 1%)
- The following common adverse reactions were reported more frequently (≥5%) in patients receiving RITUXAN following CVP compared with those who received no further therapy: fatigue (39% vs. 14%), anemia (35% vs. 20%), peripheral sensory neuropathy (30% vs. 18%), infections (19% vs. 9%), pulmonary toxicity (18% vs. 10%), hepatobiliary toxicity (17% vs. 7%), rash and/or pruritus (17% vs. 5%), arthralgia (12% vs. 3%), and weight gain (11% vs. 4%)
- RITUXAN® (Rituximab) full prescribing information, Genentech, Inc., 2014.
- Data on file, Genentech, Inc.